ESMO WCGIC 2022 | MOUNTAINEER-03: tucatinib plus trastuzumab plus FOLFOX for first-line treatment of mCRC
Jonathan Strickler, MD, Duke Cancer Institute, Durham, NC, discusses the potential of tucatinib for patients with HER2+ metastatic colorectal cancer and talks about the currently-recruiting MOUNTAINEER-03 trial (NCT05253651) which will investigate the use of tucatinib plus trastuzumab plus FOLFOX in the first-line setting. This interview took place at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer (ESMO WCGIC) 2022 in Barcelona, Spain.
Disclosures
Consultant or advisory role: Abbvie, Takeda, AstraZeneca, Bayer, GSK, Inivata, Mereo Biopharma, Natera, Pfizer, Pionyr Immunotherapeutics, Seagen, Silverback Therapeutics, Viatris, Zentalis Compensated: Yes
Research funding or contracted research: Amgen, Bayer, Erasca, Seagen, Daiichi-Sankyo, Gossamer Bio, AStar D3, Sanofi, Roche/ Genentech, Curegenix, Nektar, Abbvie, Silverback Therapeutics Compensated: No
